Cambridge Nutritional Sciences plc
(the 'Company' or 'CNS')
Grant of Options
CNS (AIM: CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that on 31st March 2025 the Board granted share options (the "Options") over its ordinary shares of 4 pence each ("Ordinary Shares") to James Cooper, Chief Executive Officer and Executive Director.
Following this grant of Options, the Company has options in issue over 26,173,182 Ordinary Shares, representing approximately 11.0% per cent. of the Company's total issued share capital.
| Director | Number of Options granted on | Exercise Price | Total options held |
|
|
|
|
|
Grant of Options
The Company has granted the Options to incentivise executive director performance for the benefit of all Shareholders.
The Options are subject to time conditions (as set out below); good/bad leaver provisions; and being a director of the Company on the date of vesting.
Options are subject to time conditions as follows:
| Proportion of Options | Normal earliest exercise date |
| 34 per cent. ("Tranche One") | On the second anniversary of 31st March 2025 |
| 33 per cent. ("Tranche Two") | On the third anniversary of 31st March 2025 |
| 33 per cent. ("Tranche Three") | On the fourth anniversary of 31st March 2025 |
For further information, please contact:
| Cambridge Nutritional Sciences Plc James Cooper, Chief Executive Officer
| investors@cnsplc.com |
| Cavendish Capital Markets Limited Geoff Nash / Edward Whiley (Corporate Finance) Nigel Birks / Harriet Ward (ECM) | Tel: 020 7220 0500 |
About Cambridge Nutritional Sciences Plc
Cambridge Nutritional Sciences Plc (AIM: CNSL) is the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name | James Cooper | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Chief Executive Officer, Executive Director | ||||
| b) | Initial notification/ | Initial Notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Cambridge Nutritional Sciences plc | ||||
| b) | LEI | 2138007U9P4BTZTYIR92 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the | Options over Ordinary Shares of 4p each | ||||
| Identification code | ISIN: GB00B1VCP282 | |||||
| b) | Nature of | Grant of Options | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price | As above | ||||
| e) | Date of the | 31st March 2025 | ||||
| f) | Place of the transactions | Outside a trading venue | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
